Journal of Shanghai Jiao Tong University (Medical Science) ›› 2022, Vol. 42 ›› Issue (12): 1745-1750.doi: 10.3969/j.issn.1674-8115.2022.12.013

• Review • Previous Articles    

Exploration on rationalization of diagnosis and treatment of breast cancer patients combined with COVID-19

ZHANG Yutang1(), JIN Yijie1, ZHANG Fengchun2, XU Yingchun1()   

  1. 1.Department of Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
    2.Department of Oncology, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou 215127, China
  • Received:2022-06-24 Accepted:2022-09-04 Online:2022-12-28 Published:2022-12-28
  • Contact: XU Yingchun;
  • Supported by:
    National Natural Science Foundation of China(81301858);Suzhou Science and Technology Project(SYS201404);Natural Science Foundation of Jiangsu Province(BK20181186)


Coronavirus disease 2019 (COVID-19) has become a major global public health event as a new acute respiratory infectious disease. During the COVID-19 pandemic, compared with the healthy population, cancer patients had a higher risk of developing comorbidities of other systems, due to their bad poor immunity and older age. Research showed that breast cancer, as a malignant disease, had the highest disease incidence in female patients. Breast cancer patients with COVID-19 infection often have worse prognosis, and they have to postpone anti-tumor treatment due to COVID-19 infection. At present, the effect of delayed treatment on the survival rate of breast cancer patients is unclear, and whether the treatment plan of these patients should be adjusted is still being studied. Through the systematic review of existing clinical research studies, the guidelines of various societies and the expert consensus, this paper reviews the selection and rationalization of breast cancer treatment options under the COVID-19 epidemic, and discusses the opportunity and approaches of anti-tumor treatment for breast cancer patients infected with COVID-19.

Key words: breast cancer, coronavirus disease 2019 (COVID-19), surgery, radiotherapy, systemic therapy

CLC Number: